NASDAQ: BCLIBrainstorm Cell Therapeutics Inc Stock
$0.51-0.03 (-5.56%)
Updated Apr 18, 2024
BCLI Price
$0.51
Fair Value Price
$0.00
Market Cap
$35.13M
52 Week Low
$0.13
52 Week High
$3.37
P/E
-1.29x
P/B
-7.23x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.19M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.87
Operating Cash Flow
-$20M
Beta
0.67
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
BCLI Overview
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how BCLI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BCLI ($0.51) is overvalued by 88,464.13% relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BCLI ($0.51) is not significantly undervalued (88,464.13%) relative to our estimate of its Fair Value price of $0.00 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BCLI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BCLI due diligence checks available for Premium users.
Be the first to know about important BCLI news, forecast changes, insider trades & much more!
BCLI News
Valuation
BCLI fair value
Fair Value of BCLI stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$0.00
Overvalued by
87,774.91%
BCLI ($0.51) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BCLI ($0.51) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BCLI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BCLI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.29x
Industry
15.68x
Market
41.33x
BCLI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-7.23x
Industry
5.76x
BCLI's financial health
Profit margin
Revenue
$0.0
Net Income
-$5.6M
Profit Margin
0%
BCLI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$4.2M
Liabilities
$9.1M
Debt to equity
-1.87
BCLI's short-term liabilities ($7.80M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BCLI's short-term assets ($1.90M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BCLI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
BCLI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.3M
Investing
$196.0k
Financing
$3.4M
BCLI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BCLI vs Biotech Stocks
Brainstorm Cell Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.